Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2023 Feb 8

PMID 36754935

Authors

Tina M Buehner

Margaret Liotta

Ronald K Potkul

Robert H Wagner

Bital Savir-Baruch

Affiliations

Soon will be listed here.

Abstract

Objective: Early and accurate staging of ovarian cancer is paramount to disease survival. Conventional imaging including FDG PET/CT are limited in the evaluation of small metastatic lesions. 18F-Fluciclovine has minimal urine and bowel excretion allowing optimal visualization of the abdomen and pelvis. This study examines 18F-fluciclovine uptake in known primary and recurrent ovarian cancer.

Methods: Seven patients with a confirmed diagnosis of epithelial ovarian cancer underwent 18F-fluciclovine PET/CT imaging. Forty-one (41) lesions were identified with 18F-fluciclovine and confirmed to be true positive (n = 41). We aim to explore if 18F-fluciclovine uptake in ovarian lesions were greater than background uptake of bone marrow, blood pool, and bladder. Quantification analysis was performed to determine max and mean standard uptake values (SUVmax and SUVmean) of known and suspected lesions compared to SUVmean uptake of background structures.

Results: 18F-Fluciclovine demonstrated 100% sensitivity (41/41) for uptake in known ovarian lesions. The average SUVmax (±SD) uptake of known ovarian lesions was 5.9 (±2.6) and 5.1 (±2.0) on early and delayed images, respectively. The average tumor SUVmax to SUVmean of background (±SD) (T:B) ratios on early and delay were 1.9 (±0.8), 2.1 (±0.9) for marrow; 3.8 (±1.8), 3.4 (±1.5) for aorta; and 8.4 (±4.3), 1.5 (±1.7) for bladder, respectively.

Conclusion: 18F-Fluciclovine uptake in malignant ovarian lesions was above background levels suggesting its feasibility in the imaging of ovarian cancer. Due to increasing tracer washout via the urinary bladder over time, early imaging at 4 min post injection is favorable.

Citing Articles

Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis.

Yin D, Jiang Y Int J Womens Health. 2023; 15:1611-1619.

PMID: 37901720 PMC: 10612500. DOI: 10.2147/IJWH.S418135.

References

Hu T, Nie D, Gou J, Li Z . Predictive significance of preoperative CT findings for suboptimal cytoreduction in advanced ovarian cancer: a meta-analysis. Cancer Manag Res. 2018; 10:2019-2030. PMC: 6053262. DOI: 10.2147/CMAR.S166658. View

Forstner R, Hricak H, Occhipinti K, Powell C, Frankel S, Stern J . Ovarian cancer: staging with CT and MR imaging. Radiology. 1995; 197(3):619-26. DOI: 10.1148/radiology.197.3.7480729. View

Nougaret S, Addley H, Colombo P, Fujii S, Al Sharif S, Tirumani S . Ovarian carcinomatosis: how the radiologist can help plan the surgical approach. Radiographics. 2012; 32(6):1775-800. DOI: 10.1148/rg.326125511. View

Forstner R, Meissnitzer M, Cunha T . Update on Imaging of Ovarian Cancer. Curr Radiol Rep. 2016; 4:31. PMC: 4826654. DOI: 10.1007/s40134-016-0157-9. View

Khiewvan B, Torigian D, Emamzadehfard S, Paydary K, Salavati A, Houshmand S . An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017; 44(6):1079-1091. DOI: 10.1007/s00259-017-3638-z. View

Feng Z, Liu S, Ju X, Chen X, Li R, Bi R . Diagnostic accuracy of F-FDG PET/CT scan for peritoneal metastases in advanced ovarian cancer. Quant Imaging Med Surg. 2021; 11(8):3392-3398. PMC: 8245942. DOI: 10.21037/qims-20-784. View

Ganapathy V, Thangaraju M, Prasad P . Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2008; 121(1):29-40. DOI: 10.1016/j.pharmthera.2008.09.005. View

Washburn L, Sun T, Byrd B, Hayes R, Butler T . 1-aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med. 1979; 20(10):1055-61. View

Okudaira H, Oka S, Ono M, Nakanishi T, Schuster D, Kobayashi M . Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol. 2014; 16(6):756-64. PMC: 5648589. DOI: 10.1007/s11307-014-0756-x. View

10.

Fuchs B, Bode B . Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?. Semin Cancer Biol. 2005; 15(4):254-66. DOI: 10.1016/j.semcancer.2005.04.005. View

11.

Kaira K, Nakamura K, Hirakawa T, Imai H, Tominaga H, Oriuchi N . Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors. Am J Transl Res. 2015; 7(6):1161-71. PMC: 4532748. View

12.

Sato K, Miyamoto M, Takano M, Furuya K, Tsuda H . Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Arch. 2019; 474(6):701-710. DOI: 10.1007/s00428-019-02520-0. View

13.

Guo H, Xu Y, Wang F, Shen Z, Tuo X, Qian H . Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer. Oncol Rep. 2018; 40(6):3725-3733. DOI: 10.3892/or.2018.6729. View

14.

Lapela M, Varpula M, Grenman S, Salmi T, Alanen K, Nagren K . Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med. 1995; 36(12):2196-200. View

15.

Schuster D, Nieh P, Jani A, Amzat R, Bowman F, Halkar R . Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2013; 191(5):1446-53. PMC: 4155751. DOI: 10.1016/j.juro.2013.10.065. View

16.

Nye J, Schuster D, Yu W, Camp V, Goodman M, Votaw J . Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med. 2007; 48(6):1017-20. DOI: 10.2967/jnumed.107.040097. View

17.

Lovrec P, Schuster D, Wagner R, Gabriel M, Savir-Baruch B . Characterizing and Mitigating Bladder Radioactivity on F-Fluciclovine PET/CT. J Nucl Med Technol. 2019; 48(1):24-29. DOI: 10.2967/jnmt.119.230581. View

18.

Robertson M, Sakellis C, Hyun H, Jacene H . Extraprostatic Uptake of F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. AJR Am J Roentgenol. 2020; 214(3):641-648. DOI: 10.2214/AJR.19.21894. View

19.

Savir-Baruch B, Zanoni L, Schuster D . Imaging of Prostate Cancer Using Fluciclovine. Urol Clin North Am. 2018; 45(3):489-502. DOI: 10.1016/j.ucl.2018.03.015. View

20.

Savir-Baruch B, Banks K, McConathy J, Molchanova-Cook O, Parent E, Takalkar A . ACR-ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. Clin Nucl Med. 2018; 43(12):909-917. DOI: 10.1097/RLU.0000000000002310. View